| Website | theravectys.com |
| Category | BioTech |
| Phone | 33-1-44-38-93-13 |
| Employees |
| TOTAL | $9.41M |
| FUNDING TOTAL | $9.41M |
| Series C, 9/12 Guy PAILLAUD John PIETERS Philippe ODDO Richard HENNESSY | €7.48M |
THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.
